Cognitive Impairment in Multiple Sclerosis.

Area of Science:

• Neuroscience
• Immunology
• Metabolic pathways

Background:

• Multiple sclerosis (MS) affects nearly 3 million globally, characterized by nervous system demyelination.
• MS prevalence has risen, increasingly recognized as a cause of cognitive loss and dementia.
• Current disease-modifying therapies manage relapses and brain volume loss but not disease progression or cognitive disability.

Purpose of the Study:

• To explore innovative strategies for treating MS-related cognitive impairment.
• To investigate novel pathways involved in inflammation, immune cell activation, and cell survival in MS.
• To identify potential therapeutic targets for MS-associated dementia and cognitive loss.

Main Methods:

• Review of pathways including programmed cell death, mammalian forkhead transcription factors (FoxOs), mechanistic target of rapamycin (mTOR), AMP-activated protein kinase (AMPK), and silent mating type information regulation 2 homolog 1 (SIRT1).
• Examination of the roles of apolipoprotein E (APOE-ε4) and SARS-CoV-2 in MS pathogenesis.
• Analysis of the interplay between these pathways and cellular metabolism, particularly nicotinamide adenine dinucleotide (NAD+).

Main Results:

• Identified interconnected pathways influencing inflammation, immune response, and cell survival in MS.
• Highlighted the critical role of metabolic pathways, including NAD+, in cellular processes relevant to MS.
• Established links between specific molecular pathways (FoxOs, mTOR, AMPK, SIRT1) and MS-related cognitive dysfunction.

Conclusions:

• Understanding these complex pathways offers new therapeutic avenues for MS.
• Targeting inflammation, immune activation, and cell survival mechanisms may prevent or reverse cognitive decline in MS patients.
• Further research into these pathways could lead to novel treatments for MS-induced dementia.